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Abstract
The role and contribution of the dense noradrenergic innervation in the ventral bed nucleus of the
stria terminalis (vBNST) and anteroventral thalamic nucleus (AV) to biological function and
animal behaviors is poorly understood due to the small size of these nuclei. The aim of this study
was to compare norepinephrine release and uptake in the vBNST with that in the AV of
anesthetized rats. Measurements were made in vivo with fast-scan cyclic voltammetry following
electrical stimulation of noradrenergic projection pathways, either the dorsal noradrenergic bundle
(DNB) or the ventral noradrenergic bundle (VNB). The substance detected was identified as
norepinephrine based upon voltammetric, anatomical, neurochemical, and pharmacological
evidence. Fast-scan cyclic voltammetry enables the selective monitoring of local norepinephrine
overflow in the vBNST evoked by the stimulation of either the DNB or VNB while
norepinephrine in the AV was only evoked by DNB stimulation. The α2-adrenoceptor antagonist,
yohimbine, and the norepinephrine uptake inhibitor, desipramine, increased norepinephrine
overflow and slowed its disappearance in both regions. However, control of extracellular
norepinephrine by both autoreceptors and uptake was greater in the AV. The greater control
exerted by autoreceptors and uptake in the AV resulted in reduced extracellular concentration
compared to the vBNST when large numbers of stimulation pulses were employed. The
differences in noradrenergic transmission observed in the terminal fields of the vBNST and the
AV may differentially regulate activity in these two regions that both contain high densities of
norepinephrine terminals.
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Introduction
Norepinephrine is involved in the regulation of a number of behaviors including learning
and memory, arousal and stress reactions to challenging environments, and drug addiction
(Onaka & Yagi, 1998; Berridge & Waterhouse, 2003; Forray & Gysling, 2004; Aston-Jones
& Cohen, 2005). Despite its important roles in the regulation of behavior, neuronal
regulation of its release and uptake has been studied far less than for dopamine. In part, this
is because the distribution of norepinephrine within the brain is diffuse (Mitchell et al.,
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1994) and high sensitivity is required for detection of its low physiological concentrations.
Brain regions that have appreciable amounts of norepinephrine are often only a few hundred
microns across (Kilts & Anderson, 1986; Palij & Stamford, 1992), further complicating
detection.
Two important noradrenergic pathways in the brain are the dorsal noradrenergic bundle
(DNB) and ventral noradrenergic bundle (VNB). The DNB primarily originates in the locus
coeruleus (LC; A6) and then merges into the medial forebrain bundle with projections to
targets that include the thalamus, hypothalamus, and cortex (Paxinos, 1995; Berridge &
Waterhouse, 2003). The VNB has its origin in the nucleus tractus solitarius (NTS; A2) and
other noradrenergic cell groups (A1, A5 and A7). It courses between the substantia nigra
and ventral tegmental area (Ungerstedt, 1971; Johnston et al., 1987) and then also merges
with the medial forebrain bundle before projecting to target regions such as the septum and
hypothalamus (Paxinos, 1995). Until they merge into the medial forebrain bundle, the VNB
and DNB are distinct (Miyahara & Oomura, 1982; Saphier, 1993), facilitating independent
excitation of each pathway by electrical stimulation. Electrically evoked norepinephrine can
be detected with fast-scan cyclic voltammetry at carbon-fiber microelectrodes (Palij &
Stamford, 1992), a technique demonstrated to be useful for monitoring the dynamics of
extracellular dopamine in the brain (Millar et al., 1985; Garris & Wightman, 1994;
Owesson-White et al., 2008). The high time resolution of this approach has enabled critical
differences in the dynamics of extracellular dopamine to be characterized in specific brain
regions such as the caudate-putamen and amygdala (Garris & Wightman, 1994). The small
size (μm range) of the chemical sensor allows a local view of the dynamics of catecholamine
release and uptake.
Here we report on norepinephrine release evoked by stimulation in the DNB and VNB.
Release was monitored in the anteroventral thalamic nucleus (AV), a region characterized in
previous work (Brun et al., 1993; Dugast et al., 2002) and compared to norepinephrine
release in the ventral bed nucleus of the stria terminalis (vBNST), a region that receives a
dense norepinephrine innervation (Oke et al., 1983). The AV plays an important role in
learning and memory while the vBNST regulates autonomic and behavioral responses
related to stress, anxiety and noxious stimuli (Onaka & Yagi, 1998; Delfs et al., 2000; Van
Groen et al., 2002). Comparison of noradrenergic transmission in the terminal fields in the
vBNST and the AV provides new insights into the regulation of extracellular norepinephrine
in these two regions that regulate very different aspects of animal behavior.
Materials and methods
Animals
Adult male Sprague-Dawley rats (320-400g) were purchased from Charles Rivers
(Wilmington, MA) and housed in temperature and humidity controlled rooms with a 12 hour
on/off light cycle. Food and water were available ad libitum. All procedures for handling
and caring for the laboratory animals were in accordance with the Guide for Care and Use of
Laboratory Animals and were approved by the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill.
Surgery
Male Sprague-Dawley rats were anesthetized with urethane (1.5 mg/kg) and immobilized in
a stereotaxic frame (David Kopf Instruments, Tujunga, CA). Temperature was maintained at
37 °C with a heating pad (Harvard Apparatus, Holliston, MA). The dorsal skull surface was
exposed, and small holes were drilled in the skull for reference (Ag/AgCl) and stimulating
electrodes as well as the carbon-fiber microelectrodes. Anteroposterior (AP), mediolateral
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(ML) and dorsoventral (DV) positions were referenced from bregma. The dura mater was
punctured, carefully removed, and a carbon-fiber microelectrode was lowered into the
BNST (AP 0.0 mm, ML +1.2 mm, DV from -6.0 to -8.0 mm), the AV (AP -2.1 mm, ML
+1.5 mm, DV from -5.0 to -6.0 mm) or the CPu (AP +1.3 mm, ML +2.0 mm, DV from -4.5
to -6.5 mm; coordinates from a stereotaxic atlas (Paxinos & Watson, 2007). An Ag/AgCl
reference electrode placed in the contralateral cortex was employed for all measurements
and it was secured on the skull with dental cement.
Electrical stimulation was accomplished with a bipolar, stainless-steel electrode (0.2 mm
diameter for each tip, the tips are separated by ∼1.0 mm, Plastics One, Roanoke, VA). The
stimulating electrode was insulated to the tip. It was placed into either the DNB (AP -5.2
mm, ML +1.2 mm, DV from -5.0 to -6.0 mm) or the VNB that is at the same AP and ML
coordinates but is ∼2 mm lower. Because the tips of the bipolar electrode were separated by
∼1.0 mm, the VNB placement also stimulated the VTA and SN (Miyahara & Oomura, 1982;
Saphier, 1993). Supplemental Figure 1 is a schematic of the ascending norepinephrine and
dopamine pathways and the sites for their respective terminal areas (Ungerstedt, 1971).
Electrical stimulation
Stimulus pulses were computer-generated (NL 800A, Neurolog, Medical Systems Corp.,
Great Neck, NY, U.S.A.) and were electrically isolated from the electrochemical system.
The electrical stimulation consisted of biphasic square wave pulses (300 μA and 2 ms each
phase) with stimulation frequencies between 10 and 60 Hz. The number of stimulus pulses
was normally held constant at 60 for the vBNST and the AV and 24 for the CPu.
Stimulations were repeated every 4 or 5 min. With this time interval, stimulation resulted in
reproducible responses for both norepinephrine and dopamine release. Shorter interval (< 2
min) resulted in diminished release.
Voltammetric procedures
Glass-encased cylindrical carbon-fiber microelectrodes and Ag/AgCl reference electrodes
were prepared as described earlier (Cahill & Wightman, 1995). T-650 untreated carbon
fibers (Thornel, Amoco Corp., Greenville, SC) with an exposed length of 75 - 100 μm and 6
μm in nominal diameter were used. fast-scan cyclic voltammetry was computer-controlled
and has been described in detail previously (Heien et al., 2003). A triangular scan (-0.4 to
+1.3 V, 400V/s) was repeated every 100 ms. Data was digitized and stored on a computer
using software written in LABVIEW (National Instruments). Background-subtracted cyclic
voltammograms were obtained by digitally subtracting voltammograms collected during
stimulation from those collected during baseline recording. Temporal responses were
determined by monitoring the current at the peak oxidation potential for norepinephrine and
dopamine in successive voltammograms. The current was converted to concentration based
on calibration curves of each carbon-fiber microelectrode obtained after the in vivo
experiment with known concentrations of dopamine and norepinephrine in vitro.
High performance liquid chromatography (HPLC)
Rats were anesthetized with urethane and decapitated. The brain was rapidly removed and
placed on ice. Coronal brain slices (500 μm thick) containing the ventral bed nucleus of the
stria terminalis (vBNST) were prepared in ice cold artificial cerebral spinal fluid (aCSF)
using a Lancer Vibratome (World Precision Instruments, Sarasota, Fl.). The aCSF contained
(in mM): 20 HEPES, 2.4 CaCl2, 1.2 MgCl2, 1.2 NaH2PO4, 2.45 KCl, 126 NaCl, 11 glucose,
and 25 NaHCO3. The pH was adjusted to pH 7.4 and the aCSF was saturated with 95% O2 /
5% CO2. Tissue samples were dissected from the brain slices containing the area of interest
(500 μm thickness). The tissue was wet weighted in a pre-tared volume of 200 μL 0.1 N
HClO4 spiked with 1 μM hydroquinone (HQ). The tissue was homogenized with a sonic
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dismembrator (Fisher Sci., Model 60, Pittsburgh, PA, USA). The homogenized tissue was
centrifuged at 6000 rpm for 10 min and the supernatant was removed and filtered using a
0.2-μm syringe microfilter (Millex-LG). Injections (10 μL) were made onto a reverse phase
column (C-18, 5 μm, 4.6 × 250 mm, Waters symmetry 300). The mobile phase (prepared in
HPLC grade water) contained 0.1 M citric acid, 1 mM hexyl sodium sulfate, 0.1 mm EDTA,
and 10% methanol (pH 3.5) at a flow rate of 1 mL/min. Catecholamines were detected with
a thin-layer radial electrochemical cell (BASi, West Lafayette, IN, USA) at a potential of
700 mV versus a Ag/AgCl reference electrode. Catecholamine standards were prepared
from 10 mM stock solutions in 0.1 N HClO4. A Labview stripchart recorder program
(Jorgenson Lab, UNC-CH) was used for data collection through home built electronic
equipment. The peak area of the analyte was ratioed to the peak area of the internal standard,
HQ. After correction for differential detector response, the amount of analyte in the brain
tissue was calculated.
Lidocaine microinfusion
Lidocaine was administered via an infusion cannula (33 gauge) that was combined with the
bipolar stimulating electrodes and inserted into the implanted guide cannula (26 gauge,
Plastics One Inc., VA, USA). Microinfusions (0.5 μL) were made over 60 s with a syringe
pump (Kent Scientific Corporation, CT, USA). The regions targeted were normally the
noradrenergic pathways, DNB and VNB. In one set of experiments, the noradrenergic cell
bodies in the LC (AP -9.8 mm, ML +1.4 mm, DV 6.5-7.5 mm) and the NTS (AP -12.0 mm,
ML +1.8 mm, DV 7.6-8.6 mm) were targeted.
Histology
At the end of experiments, electrode placements were verified by stereotaxically lowering a
tungsten electrode to the original position of the carbon-fiber microelectrode. A lesion was
made at the recording site by applying continuous current (20 μA for 10 s) to the tungsten
electrode. Some lesions (> 20 rats) of the vBNST and the AV were made directly with the
carbon-fiber microelectrodes, but this precluded postcalibration of the electrode sensitivity.
These experiments verified the accuracy of the repositioning of tungsten electrodes in
recording sites. Brains were removed from the skull, stored in 10 % formaldehyde for at
least 3 days, and coronally sectioned into 40 μm slices with a cryostat. The sections were
mounted on slides, stained with 0.2 % thionin, and coverslipped before viewing under a light
microscope.
Drugs and reagents
All chemicals and drugs were reagent-quality or better and were used without additional
purification. Drugs were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless
otherwise indicated. In vitro postcalibration of carbon-fiber microelectrodes was performed
in a Tris buffer solution at a pH 7.4 containing 15 mM Tris, 140 mM NaCl, 3.25 mM KCl,
1.2 mM CaCl2, 1.25 mM NaH2PO4, 1.2 mM MgCl2, and 2.0 mM Na2SO4 in double
distilled water (Mega Pure System, Corning Glasswork, Corning, NY). Lidocaine (100 μg/
0.5 μL) was dissolved in saline and sterile filtered with the pH adjusted to 6 with NaOH.
Desipramine-HCl, raclopride-HCl, clonidine-HCl and yohimbine-HCl were dissolved in
saline. GBR 12909-HCl was dissolved in double distilled water and then diluted with saline.
Injected volumes were 0.6 ml/kg and were given intraperitoneally (i.p.).
Data analysis
Clampfit 8.1 as part of pCLAMP 8.1 software package (Axon Instruments, Foster City, CA)
was used to analyze half-life and signal amplitude values according to procedures described
in the literature (Park et al. 2005). The half life of catecholamine uptake, t1/2, was taken as
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the time to descend from its maximum value to half of that value. Since uptake follows
Michaelis-Menten kinetics, this procedure is an oversimplification. Nevertheless, we used it
to obtain figures that give an approximate measure of the changes in data induced by the
various drugs. Data are represented as mean ± S.E.M. and ‘n’ values indicating the number
of rats. Mean values were compared by using the two-tailed Student's t-test (GraphPad
Software version 4.0, San Diego, CA, USA) to calculate the level of significance. P < 0.05
was regarded as statistically significant.
Results
Monoamine content of the vBNST
Two regions of vBNST were dissected from fresh brains and their monoamine
(norepinephrine, dopamine and serotonin) content determined by HPLC (Table 1). The ratio
of norepinephrine to dopamine content for the anteromedial vBNST (AP +0.5 to 0.0 mm
from bregma) was ca. 2 to 1 whereas in the medioposterior vBNST region (AP 0.0 to -0.5
mm from bregma) it was ca. 10 to 1 consistent with a previous report (Kilts & Anderson,
1986). Serotonin was not detected in either subregion. The norepinephrine content in the
medioposterior vBNST (3.25 ± 1.89 μg/g of tissue) is similar to the 2.1 μg/g of tissue
previously found in the AV (Mitchell et al., 1994), a region that also contains negligible
dopamine (Oke et al., 1983). The relatively large standard deviation for the neurochemical
values in the vBNST is atypical of liquid chromatographic measurements and may well
reflect the heterogeneity of this region and our failure to dissect exactly the same nuclei each
time (the site in the vBNST that supports norepinephrine release is ∼300 μm thick).
However, the norepinephrine content in both of these regions is considerably less than the
content of dopamine (9 μg/g of tissue) in the CPu, a region that contains little
norepinephrine (Garris & Wightman, 1994).
Catecholamine overflow in the vBNST and AV as a function of stimulating electrode depth
In the first set of in vivo experiments, the carbon-fiber microelectrode was placed in the
vBNST or AV while the stimulating electrode was lowered from 3.5 mm below the skull
surface. Based on catecholamine content of vBNST, we lowered the carbon-fiber
microelectrode in the medioposterior vBNST to monitor extracellular norepinephrine as
shown in supplementary Figure 2.
Catecholamine overflow was monitored while the electrical stimulation was delivered at
different depths. Stimulations (60 Hz, 60 pulses) were delivered at 200-300 μm intervals.
Figure 1A shows the coronal plane (AP -5.2 mm) and track (dotted lines, centered on 1.2
mm ML) of the tips of the bipolar stimulating electrode. The DNB is located ∼2 mm above
the VTA/SN while the VNB passes within the VTA/SN (Ungerstedt, 1971; Miyahara &
Oomura, 1982; Saphier, 1993). The maximum current in the cyclic voltammograms at the
potential where catecholamines are oxidized (0.6 V vs Ag/AgCl) was recorded and plotted
as a function of the position of the stimulating electrode (Figure 1B).
When the carbon-fiber microelectrode was in the vBNST responses were not observed until
the stimulating electrode was below a depth of 5 mm. Evoked release reached an initial
maximum at depths of 5.5-7.0 mm, the location of the DNB (Figure 1B) and a second
maximal release was evoked between 8.2 and 8.8 mm beneath the skull surface, the location
of the VNB. When at the level of the VNB, the stimulating electrode tips are in close
proximity to the VTA/SN. Indeed, the dopamine cell bodies are also activated with VNB
stimulation since catecholamine release was evoked in the CPu, a region containing little
norepinephrine. DNB stimulation does not evoke catecholamine release in the CPu (Garris
et al., 1993). When the carbon-fiber microelectrode was in the AV, maximal release was
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also observed with the stimulating electrode in the DNB (between 5.5 and 7.0 mm).
However, catecholamine release in the AV was not detected when the stimulating electrode
was at the level of the VNB. Individual traces and background-subtracted cyclic
voltammograms recorded in the vBNST and AV along with their respective cyclic
voltammograms are shown in Figure 1C.
The cyclic voltammograms recorded in different terminal regions are compared to authentic
dopamine and norepinephrine in Figure 2. Although slight differences exist, within
experimental error dopamine and norepinephrine cannot be distinguished based on their
voltammograms. However, the cyclic voltammograms for the catecholamines are distinct
from those for all other substances establishing that the evoked release is a catecholamine
(Heien et al., 2003). The signal for norepinephrine at a specific concentration is only 60 %
of that for dopamine because it adsorbs to the electrode to a lesser extent (Heien et al.,
2004).
Spatial distribution of evoked norepinephrine by stimulation of the DNB or VNB
In the next series of experiments the stimulating electrode was fixed at a location in the
DNB or the VNB while the carbon-fiber microelectrode was lowered through terminal
regions. Figure 3A shows the coronal plane (AP 0.0 mm) that was used for investigating
catecholamine release along a track that includes the vBNST. The carbon-fiber
microelectrode was lowered from 4.2 to 8.5 mm below the skull surface (track shown by a
dotted line in Figure 3A (left), 1.2 mm ML), and cyclic voltammograms were recorded at
different vertical positions during electrical stimulations (60 Hz, 60 pulses). When the VNB
was stimulated, catecholamine release was seen in two regions of the BNST as the carbon-
fiber microelectrode was lowered (Figure 3A, right). Catecholamine overflow was maximal
at ∼6.0 mm, the level of the dorsal BNST (dBNST), disappeared at the level of the anterior
commissure, and then reached a maximal response at ∼7.3 mm, the level of the vBNST.
When the stimulating electrode was in the DNB, only low release was evoked in the
dBNST, none was seen at the level of the anterior commissure, and catecholamine release
was maximal at the level of the vBNST (Figure 3A right). The responses in the vBNST were
lower with the carbon fiber further posterior (AP - 0.4 to - 0.7 mm, data not shown),
consistent with previous work (Forray & Gysling, 2004).
Figure 3B shows the coronal section containing the AV (AP -2.2 mm) in which the carbon-
fiber microelectrode was lowered (ML 1.5 mm) from 4.2 to 7.2 mm from the skull surface
while stimulated release was evoked as described above. The AV is at 4.9 to 5.7 mm along
this tract. When the stimulating electrode was placed in the DNB, maximal catecholamine
release was observed at 5.5 mm below the skull surface, coincident with the AV (Figure 3B,
right). No release was seen below 6.2 mm. When the stimulating electrode was in the VNB,
there was no detectable signal in the AV with the exception of a small signal in one out of
six rats. This result is consistent with previous studies that catecholamine input into the AV
is primarily through the DNB (Kobayashi et al., 1974; Brun et al., 1993).
Effect of autoreceptor antagonists and uptake blockers on catecholamine overflow in the
AV and the CPu
To confirm the origin of the signals in the AV, we tested the effects of drugs known to act at
noradrenergic neurons and compared their responses to drugs with known actions at
dopaminergic neurons. α2-adrenoceptors down-regulate norepinephrine release, a process
that is blocked by the antagonist yohimbine (Ghasemzadeh et al., 1993). D2 receptors play a
similar role on dopamine neurons where they act as autoreceptors and inhibit release. Thus,
raclopride, a D2 antagonist, increases stimulated release from dopamine neurons (Seeman &
Van Tol, 1993), but does not affect release from norepinephrine neurons (Gobert et al.,
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1998). Desipramine selectively inhibits the norepinephrine transporter (NET), reducing the
clearance rate of norepinephrine (Dugast et al., 2002), but it does not affect the dopamine
transporter (DAT) (Kula et al., 1999). In contrast, GBR12909 blocks the DAT while it has
no affect on the NET (Palij & Stamford, 1992; Dugast et al., 2002).
The effects of noradrenergic drugs on stimulated release were evaluated in the AV (60
pulses, 60 Hz) and compared to dopaminergic responses in the CPu (24 pulses at 60 Hz,
representative examples in Figure 4). Before drug administration the clearance half-life (t1/2,
the time required for the concentration to decay to 50 % of the maximum) in the AV was
1.28 ± 0.11 s (n = 15) in close agreement with that reported previously (Mitchell et al.,
1994). The half-life for catecholamine in the CPu was 0.83 ± 0.05 sec (n = 7) was almost
half of that in the AV (t = 2.70, d.f. = 20, P = 0.01). Overflow in the AV was significantly
increased 30 min after yohimbine (5 mg/kg). These changes were quantified by recording
the maximal evoked release [CA]max and t1/2. These are reported as a percent of predrug
values in Table 2. Both parameters significantly increased after yohimbine in the AV.
Injection of desipramine (15 mg/kg) 30 min after yohimbine further increased [CA]max and
t1/2. The effects of the drugs were apparent within 10 min of administration and reached a
maximum value at ∼30 min. Desipramine (15 mg/kg) alone, also significantly increased
both [CA]max and t1/2 in the AV. Note that the noradrenergic drugs at the same doses did not
significantly change dopamine overflow in the CPu elicited by VTA/SN stimulations
(Figure 4A, right, Table 2).
When dopaminergic drugs were applied, changes in stimulated release were only observed
in the CPu with VTA/SN stimulation, but not in the AV with DNB stimulation (Table 2).
The evoked response in the AV was not significantly changed by raclopride (2 mg/kg) or
GBR 12909 (15 mg/kg)(Figure 4B, left). This work is consistent with prior results showing
that electrically stimulated release in the AV is sensitive to drugs specific for the
noradrenergic system but insensitive to drugs that affect dopaminergic neurons (Stamford et
al., 1988;Brun et al., 1993). In contrast, both [CA]max and t1/2 in the CPu were significantly
increased after the raclopride (Figure 4B, right). Administration of GBR 12909, 30 min after
raclopride, dramatically increased stimulated catecholamine overflow in the CPu. Evoked
catecholamine overflow during control experiments with saline injection was stable and
reproducible for at least 2 h (data not shown).
Pharmacological characterization of catecholamine overflow in the vBNST
While evoked release in the vBNST has been pharmacologically characterized in brain slices
(Palij & Stamford, 1992; 1993), it has not in vivo. Therefore, evoked catecholamine release
in the vBNST was also evaluated with noradrenergic specific (yohimbine, desipramine and
the norepinephrine α2-adrenoceptor agonist, clonidine) and dopamine specific (raclopride
and GBR 12909) drugs using both DNB and VNB stimulations (60 Hz, 60 pulses). Before
drug administration, norepinephrine clearance in the vBNST had t1/2 of 2.45 ± 0.19 sec (n =
8) for VNB and 2.19 ± 0.16 sec (n = 9) for DNB stimulations, values that are not
significantly different from each other but that are significantly greater than in the AV (t =
5.73, d.f. = 21, P < 0.0001 for VNB and t = 4.83, d.f. = 22, P < 0.0001 for DNB). The half
lives for catecholamine clearance before drugs in the vBNST with stimulation of either
noradrenergic pathway were almost 3 times longer than in the CPu (t = 7.74, d.f. = 13, P <
0.0001 for VNB and t = 7.23, d.f. = 14, P < 0.0001 for DNB). Evoked release was
significantly decreased 30 min after clonidine injection (0.2 mg/kg) with either DNB or
VNB stimulations, a decrease that was reversed by yohimbine administration (5.0 mg/kg,
Figure 5A). When yohimbine was administered alone, evoked release was significantly
increased 30 min later (Figure 5B) with stimulations of both pathways. These responses
were further increased with injection of desipramine 30 min later. The average results from
all animals (Table 2) show that both [CA]max and t1/2 were significantly increased by the
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noradrenergic drugs. However, the effects of desipramine and yohimbine on [CA]max and
t1/2 in the vBNST were significantly less than in the AV (Table 2). Catecholamine overflow
evoked by DNB or VNB stimulation in the vBNST was not changed by raclopride (2 mg/kg)
or GBR 12909 (15 mg/kg, Figure 5C, Table 2).
After the experiments with yohimbine and desipramine in the vBNST, catecholamine
overflow evoked by the stimulation of the DNB and the VNB was recorded for 20 min at 5
min intervals and, then, lidocaine (350 nmol) was microinfused onto the electrical
stimulation tips. Lidocaine is a voltage-gated Na+ channel blocker that prevents action
potential generation (Boehnke & Rasmusson, 2001). It eliminated stimulated release within
5 min after its microinfusion (Figure 6) and stimulated release was partially restored 30 min
later. Identical results were obtained when the stimulating electrode and microinfusion were
placed in the noradrenergic cell bodies, either the LC or the NTS. Thus, catecholamine
overflow in the vBNST is due to the neuronal responses originating from both the NTS and
the LC.
Effects of the stimulation conditions on catecholamine overflow
The responses in each noradrenergic region to different stimulation parameters were
investigated. Figure 7A shows that the amplitude increased in the AV and the vBNST with
increasing stimulation frequency (10, 20, 40, and 60 Hz, 60 pulses). The evoked
concentration change during a 20 Hz stimulation in the AV approached a plateau while the
concentration change in the vBNST continued to increase during the stimulation. However,
at higher frequencies in both regions the concentration increased during the stimulation.
Figure 7B shows the responses in the vBNST and the AV with different pulse numbers (10,
20, 40 and 80 and 120 pulses at 60 Hz). Measurable responses (signal to noise (S/N) ≥ 5)
were normally observed with at least 10 pulses at 60 Hz with our present instrumentation.
The extracellular catecholamine concentration evoked by both DNB and VNB stimulation in
the vBNST increased with pulse number but the stimulated release in the AV did not
increase when more than 40 pulses were used. Pooled maximal responses are shown in
Figure 7C and D. The maximum evoked catecholamine concentration ([CA]max) at 60 Hz,
40 pulses in the CPu with stimulation at the level of the VNB was ∼11 times greater than in
the vBNST and AV in Table 3.
Discussion
This study provides novel neurochemical information for two brain regions, the AV and
vBNST, that receive high densities of noradrenergic input. The AV receives major input
from the hippocampal formation via the mammillary bodies of the hypothalamus and has
reciprocal connections with limbic circuits. While the functional significance of
norepinephrine signaling in the AV has not been extensively studied, it is thought to play an
important role in behavioral learning and memory and the conscious perception of emotion
(Gabriel et al., 1980; Sparenborg & Gabriel, 1992; Oda et al., 2003). Conversely, the BNST
is highly connected to the ventral subiculum of the hippocampus, neocortex, the
paraventricular and supraoptic nucleus of the hypothalamus, the ventral tegmental area and
other limbic structures such as the amygdala (Dong & Swanson, 2004; Forray & Gysling,
2004; Massi et al., 2008). The norepinephrine input to vBNST plays a key role in stress and
drug related behaviors (Delfs et al., 2000; Fendt et al., 2005). However, investigation of
noradrenergic transmission within the AV and vBNST is extremely difficult because of the
small size of these nuclei. The present study provides a foundation for studies of
norepinephrine communication in animal behaviors such as learning and fear in these brain
regions. The results clearly show that norepinephrine neurotransmission has regionally
specific characteristics in discrete regions of the brain that can be monitored with carbon-
fiber microelectrodes and fast-scan cyclic voltammetry. The select positioning of stimulating
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electrodes in either noradrenergic pathways (Figure 1) or cell body regions (Figure 6) allows
characterization of noradrenergic afferents that innervate small brain regions such as the AV
and vBNST.
These two regions were selected for this initial study because their norepinephrine content is
high relative to dopamine. Moreover, measurements in brain slices have shown that
norepinephrine release in the vBNST can be evoked with local stimulation and have
identified the pharmacological control points in these regions (Palij & Stamford, 1992;
1993; Miles et al., 2002). Our brain mapping and pharmacological investigations in the
intact animal expand upon that work. A major finding is that the noradrenergic inputs into
the vBNST from both the DNB and VNB provide have quite similar capacity for release.
We also found that control by autoreceptors and NET is quite similar for the neurons of both
pathways into the vBNST. In contrast, the regulation of release and uptake was strikingly
different in the AV, a region only innervated by the DNB.
Evidence that the monitored signal in the vBNST and the AV is a catecholamine
The background-subtracted cyclic voltammograms provide a “fingerprint” that identifies the
released substance(s) as a catecholamine (Figure 2). These cyclic voltammograms enable the
catecholamines to be distinguished from other substances such as serotonin, ascorbic acid,
and catecholamine metabolites (Palij & Stamford, 1992;Heien et al., 2003). Another
approach that has been used to monitor norepinephrine is differential pulse amperometry
(Suaud-Chagny et al., 1990;Brun et al., 1993). This method can resolve catecholamines
from ascorbate but not from their metabolites and suffers from a slow response time.
Continuous amperometry has also been used (Dugast et al., 2002;Yavich et al., 2005). This
approach has little chemical selectivity but can be used to establish that the half-life of
evoked norepinephrine and dopamine is on the time scale of seconds.
Unfortunately, like all other electrochemical techniques, background-subtracted cyclic
voltammograms cannot distinguish between norepinephrine and dopamine although the
cyclic voltammograms enable the catecholamines to be distinguished from the other
substances as mentioned above. Epinephrine also has similar electrochemical properties to
dopamine and norepinephrine but the epinephrine tissue content is sufficiently low in the
brain regions investigated that it is unlikely to be measured (Van der Gugten et al., 1976;
Kilts & Anderson, 1986). Our assignment of the evoked signals measured in the AV and
vBNST to norepinephrine thus relies heavily on the neurochemical results (Table 1) that
show that dopamine is a minority catecholamine in each region (Oke et al., 1983; Kilts &
Anderson, 1986; Mitchell et al., 1994). Furthermore, immunofluorescence and
autoradiographic tracing have shown that the AV and the vBNST receive few dopaminergic
terminals (Segal et al., 1973; Swanson & Hartman, 1975; Versteeg et al., 1976; Freedman &
Cassell, 1994; Kozicz, 2001). However, we are hesitant to assign the species detected in
regions where the tissue content of dopamine and norepinephrine is similar or has not been
established even when the cyclic voltammograms have the characteristic shape of a
catecholamine. For example, release seen in the dBNST with VNB stimulation (Figure 3A),
a region that contains similar amounts of dopamine and norepinephrine (Kilts & Anderson,
1986), likely contains a dopamine component because the VNB stimulation also excites
dopamine cell bodies in the VTA/SN.
Mapping inputs to the AV and vBNST
The small size of the carbon-fiber microelectrode enables maps to be generated of sites that
support catecholamine release with up to 100 μm resolution, and enable in vivo tracking of
neuronal pathways. While such maps have been generated previously for dopamine
pathways (Garris et al., 1994; Garris & Wightman, 1994), their use to explore
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norepinephrine (Suaud-Chagny et al., 1986) innervation is less extensive. When the carbon-
fiber microelectrode was implanted either within the vBNST or the AV, electrical
stimulation of the DNB, the pathway of the noradrenergic neurons from the LC and other
nuclei (Kobayashi et al., 1974; Moore & Bloom, 1979), evoked catecholamine release in
both brain regions (Figure 3). Prior work has shown that this stimulation location does not
support release in the CPu (Garris et al., 1993). When the stimulating electrode was lowered
to the VNB, robust catecholamine release was observed in the vBNST, but no release was
observed in the AV. This is consistent with the lack of VNB noradrenergic projections to the
AV (Moore & Card, 1984). The VNB stimulation also evoked release in the CPu because
the cell bodies for dopamine, the predominant catecholamine in this region, are in the VTA/
SN which is also stimulated at the coordinates we used for the VNB. Thus, the absence of a
response in the AV also confirms that it lacks dopaminergic inputs.
The VNB noradrenergic input into the vBNST has been demonstrated by retrograde labeling
(Terenzi & Ingram, 1995; Delfs et al., 2000; Forray et al., 2000). This assignment is
supported by our pharmacological, voltammetric, and neurochemical measurements that
show that the catecholamine detected is norepinephrine and not dopamine even though we
were directly activating dopamine neurons with the site we selected for VNB stimulation.
More surprising is the robust norepinephrine release obtained with DNB stimulation. These
findings are consistent with anatomical evidence of a projection to the vBNST from the LC
(Lindvall & Stenevi, 1978; McNaughton & Mason, 1980) via the DNB (Moore, 1978;
Phelix et al., 1992), a concept suggested by Adams and coworkers (Mitchell et al., 1994). In
support of the dual noradrenergic inputs to the vBNST, norepinephrine release was evoked
by both the direct stimulation of the LC and the NTS (Figure 6), the origins of the two
pathways. Despite similar amounts available for release in the vBNST from the two
pathways, it appears that they are activated by different conditions during animal behaviors.
For example, during opiate withdrawal, the noradrenergic neurons of the VNB are
stimulated to a greater degree than those of the DNB (Delfs et al., 2000)
Comparison of stimulated norepinephrine release in the AV and vBNST
The various stimulation parameters and pharmacological agents that we employed revealed
significant differences in the characteristics of release and uptake in these two
norepinephrine rich regions. The rapid time resolution of the recordings at carbon-fiber
microelectrodes enabled the dynamics of release and uptake to be characterized with
subsecond temporal resolution, revealing these differences. The pharmacological studies
reveal that release and uptake in both regions is affected by noradrenergic drugs providing
additional evidence that the observed release is norepinephrine. Furthermore, release in both
regions is unaffected by dopaminergic drugs at doses that are highly effective in the
modulation of dopamine release in the striatum. Indeed, the high selectivity of the drugs
used in this work for the dopaminergic and noradrenergic pathways indicates that they can
be used to distinguish dopamine and norepinephrine release as long as autoreceptors and the
NET or DAT are exerting exclusive control on extracellular catecholamine levels.
The half-life measurements for norepinephrine disappearance after evoked release suggest
that uptake is approximately twice as fast in the AV as in the vBNST. The sensitivity of the
clearance to desipramine in both regions, coupled with their insensitivity to GBR 12909,
clearly shows that clearance is due to uptake mediated by NET. While the absolute values of
t1/2 given in the Results section are not corrected for the response time of the electrode, they
do show similar trends to those reported previously with continuous amperometry. In accord
with our findings, norepinephrine uptake in the AV was reported to be significantly slower
than for dopamine uptake in the striatum (Dugast et al., 1994; Dugast et al., 2002). Slower
uptake allows extrasynaptic neurotransmitters to participate in volume transmission because
they can diffuse greater distances before removal from the extracellular fluid by the
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transporter. Interestingly, the measured half-life for clearance measured in the vBNST was
independent of the noradrenergic pathway stimulated. Thus, it appears that the same uptake
sites are controlling uptake, irrespective of the pathway from which release originates.
The inhibition of the α2-adrenoceptor increased release evoked by VNB stimulation in the
vBNST and by DNB stimulation in both the AV and vBNST. However, the increase in
release was significantly greater in the AV than with stimulation of either pathway
innervating the vBNST (Table 2), indicating stronger control by noradrenergic autoreceptors
in the AV. Thus, release and uptake by autoreceptors and NET are both more tightly
regulated in the AV compared to the vBNST.
In addition to the greater control of extracellular norepinephrine in the AV evidenced by
pharmacological studies, there are notable differences in the release evoked in each region.
DNB stimulation causes similar amounts of release in each region (Table 3). Furthermore,
VNB stimulation, which does not evoke release in the AV, causes release of a similar
concentration in the vBNST. In the vBNST the frequency dependence of release is quite
similar to that reported in dopamine regions (Garris & Wightman, 1994). During low
frequency stimulations (10-20 Hz), which are in the physiological range, norepinephrine
concentrations approach a new, steady-state level during the stimulation (Figure 7). This
behavior is that expected for neurotransmitter systems in which extracellular levels are
maintained by the balance between uptake and release. At higher frequencies release takes
more pulses to overwhelm uptake, and evoked concentrations continue to rise during the
stimulation in the vBNST. However, in the AV, the stronger uptake coupled with the greater
inhibition by autoreceptors, results in a greater control of norepinephrine concentrations
during long stimulations leading to a lack of sensitivity to pulse number even with
frequencies as high as 60 Hz stimulations (Figure 7). The importance of uptake control in
the AV is clearly apparent with the dramatic increase in release amplitude following NET
inhibition (Table 2). Thus, norepinephrine response in the AV resembles that at the rat tail
artery where norepinephrine shows strong control by uptake (Msghina et al., 1999), with
additional control of extracellular levels by the noradrenergic autoreceptor.
Conclusion
In the present study, we showed that in vivo fast-scan cyclic voltammetry coupled with
carbon-fiber microelectrodes enable monitoring of rapid changes in norepinephrine
concentration in the vBNST and the AV of anesthetized rats despite the small size of these
regions and the low amounts of norepinephrine compared to that of dopamine in the
striatum. This study also demonstrates that norepinephrine release in the vBNST was evoked
by the stimulation of either DNB or VNB whereas only DNB stimulation evoked
norepinephrine release in the AV. In both regions, released norepinephrine was regulated by
autoreceptors and restored to prestimulus levels by uptake. However, control by
autoreceptors and uptake was much stronger in the AV than in the vBNST.
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vBNST ventral bed nucleus of the stria terminalis
AV anteroventral thalamic nucleus
DNB dorsal noradrenergic bundle
VNB ventral noradrenergic bundle
VTA/SN ventral tegmental area/substantia nigra
NET norepinephrine transporter
DAT dopamine transporter
LC the locus coeruleus
NTS nucleus tractus solitarius
CPu cadate-putamen
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Maps of maximal stimulated release of catecholamines measured in the AV and the vBNST
as a function of depth of the stimulating electrode. A. The dotted lines show the approximate
track of each of the two poles of the stimulating electrode. They are superimposed on a
coronal section containing the DNB and into the VTA/SN and VNB. Abbreviations used:
DNB, dorsal noradrenergic bundle; VNB, ventral noradrenergic bundle; VTA, ventral
tegmental area; SN, substantia nigra. The coronal section is from the atlas of Paxinos and
Watson (2007). B. Maximal stimulated release during electrical stimulations (60 Hz, 60
pulses) measured in the vBNST (—) and the AV (---) as the stimulating electrode was
lowered in small increments through the regions shown in (A). The relative response is the
response at a particular depth (Idx) divided by the maximum response (Idmax). Note that the
distance scale is different in panels A and B. C. Representative individual responses at the
peak current for catecholamines in the BNST (left) and the AV (right) measured at the depth
indicated in mm. The bars under the current traces denote the period of electrical
stimulation. Insets: Background-subtracted cyclic voltammograms measured during the
evoked responses. The concentration bars are based on postcalibration in norepinephrine
solutions.
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Background-subtracted cyclic voltammograms measured in the BNST, the AV and the CPu
at the end of DNB or VTA/SN and VNB stimulations (60 Hz, 60 pulses). In the upper trace,
cyclic voltammograms are also shown for authentic norepinephrine (⋯) and dopamine (---,
both at 4 μM) in a Tris buffer solution at a pH 7.4 recorded after in vivo measurement.
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Maps of stimulated norepinephrine release within the AV and BNST with stimulation of the
VNB and DNB. A. The dotted line in the coronal section (AP 0.0 mm from bregma)
illustrate the approximate path of the carbon-fiber microelectrodes in the BNST aimed at the
dorsal (d, hatched area above the ACA) and ventral (v, filled region below the ACA) BNST.
The right part of the figure shows maximal evoked responses detected in the cyclic
voltammograms following electrical stimulation (60 Hz, 60 pulses) of the VNB (⋯) or the
DNB (—). Data are normalized as in Figure 1. B. The dotted line in the coronal section (AP
-2.2 mm from bregma) shows the approximate path of the carbon-fiber microelectrodes in
the AV (filled region). The right part of the figure shows maximal evoked responses from
the cyclic voltammograms recorded after electrical stimulation (60 Hz, 60 pulses) of the
VNB (⋯) or the DNB (—). Data normalized as in Figure 1. The coronal sections were taken
from the atlas of Paxinos and Watson (2007). Abbreviations used: ACA, anterior
commissure; CPu, caudate-putamen; LV, lateral ventricle; VTN, ventral thalamic nucleus.
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Effect of yohimbine (Yo, 5 mg/kg), desipramine (DMI, 15 mg/kg), raclopride (Ra, 2 mg/kg)
and GBR 12909 (GBR, 15 mg/kg) on catecholamine overflow in the AV and the CPu. A.
Recordings of extracellular catecholamine in the AV (left) evoked by DNB stimulation with
60 pulses and in the CPu (right) evoked by VTA/SN stimulation with 24 pulses in the
absence and presence of Yo (---) and Yo + DMI (⋯) at 60 Hz. B. Recordings of extracellular
catecholamine in the AV (left) evoked by the DNB stimulation with 60 pulses and in the
CPu (right) evoked by VTA/SN stimulation with 24 pulses in the absence and presence of
Ra (---) and Ra + GBR (⋯) at 60 Hz. The bars under the current traces indicate the period of
electrical stimulation.
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Effect of clonidine (Cl, 0.2 mg/kg), yohimbine (Yo, 5 mg/kg), desipramine (DMI, 15 mg/
kg), raclopride (Ra, 2 mg/kg) and GBR 12909 (GBR, 15 mg/kg) on catecholamine overflow
in the vBNST. Representative recordings of extracellular catecholamine in the vBNST
evoked by DNB stimulation (left) or VNB stimulation (right) in the absence and presence of
(A) Cl (---) and Cl + Yo (⋯), (B) Yo (---) and Yo + DMI (⋯) and (C) Ra (---) and Ra +
GBR 12909 (⋯) at 60 Hz with 60 pulses. The bars under the current traces indicate the
period of electrical stimulation.
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Effect of lidocaine on catecholamine response in the vBNST after drug study (Yo + DMI).
Catecholamine response in the vBNST before (left), 5 min after (middle) and 30 min after
(right) lidocaine (350 nmol/min) infused into the sites of the electrical stimulation (DNB,
VNB, LC and NTS – one site per animal). An infusion cannula was combined with the
bipolar stimulating electrodes. Abbreviations used: DNB, dorsal noradrenergic bundle;
VNB, ventral noradrenergic bundle; LC, locus coeruleus; NTS, nucleus tractus solitarius.
The bars under the current traces indicate the period of electrical stimulation.
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Effect of frequency and pulse number (stimulus duration) on catecholamine overflow. A.
Individual catecholamine overflows in the AV (left) evoked by DNB stimulation and in the
vBNST evoked by DNB and VNB stimulation (right) for pulse frequency (10, 20, 40 and 60
Hz) with 60 pulses. B. Effect of pulse number (10, 20, 40, 80 and 120 for vBNST) on
catecholamine in the AV (left) and in the vBNST (right) is shown. Initiation and termination
of stimuli were indicated by the boxes. C. Maximal catecholamine responses in the AV and
the vBNST as a function of stimulation frequency. D. Maximal catecholamine responses in
the AV and vBNST as a function of pulse number. Relative responses in C and D are the
monitored response (Ix) divided by the maximum response (Imax).
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Table 1
Monoamine content in the vBNST. Values represent the mean ± S.E.M.
vBNST AnteroMedial(μg/g, n = 12 trials)
MedioPosterior
(μg/g, n = 12 trials)
Norepinephrine 2.01 ± 0.75* 3.25 ± 1.89*
Dopamine 1.18 ± 0.25 0.34 ± 0.29 #
Serotonin n.d. n.d.
*
Indicates significantly different from dopamine (P < 0.05) in the MedioPosterior.
#
Significantly different from dopamine in the AnteroMedial vBNST (t = 2.2, d.f. = 22, P = 0.04). n.d. : not detectable.
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Table 3
[CA]max in the vBNST, the AV and the CPu evoked by the electrical stimulation (60 Hz, 40 pulses). Values
represent the mean ± S.E.M. (n ≥ 7).
AV vBNST CPu
Stimulation site DNB VNB DNB VNB
[CA]max μM 0.13 ± 0.02 0.15 ± 0.01 0.17 ± 0.02 1.85 ± 0.32*
[CA]max is maximum extracellular catecholamine concentration.
*
Indicates significant difference of [CA]max evoked by the electrical stimulation in the CPu from that in the vBNST (t = 5.2, d.f. = 12, P = 0.0002)
and the AV (t = 5.7, d.f. = 13, P < 0.0001).
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